Indegene Expands Omnichannel Software and Commercial Solutions Portfolio Through Acquisition of Skura Corporation’s Life Science Business
Indegene, a global healthcare solutions provider, has completed the acquisition of Skura Corporation – a global leader in adaptive sales enablement technology for life science organizations. Skura’s SFX platform offers next-generation predictive analytics, ensuring the right message reaches the right person at the right time, increasing sales and customer success.
Indegene expands MCM technology portfolio through acquisition of Skura Corporation. Acquisition expands the company’s multi-channel technology suite for life sciences, product development capabilities in North America, and global customer base.
Launched in 1996, Skura has 35 employees and its software is used by about 40,000 medical representatives in North America. The company earned revenue of $7 million at the last count.
With this acquisition, Indegene is targeting $250 million in revenue by 2020 and considering an initial public offering on Nasdaq. In 2012, it acquired Aptillon for $4 million, and in 2014 it acquired outcome research and clinical engagement services company Total Therapeutics.
Over the years, life science companies have dramatically altered their sales and marketing strategy to align better with the changed regulatory environment rise of digital, and the changing needs of healthcare providers (HCPs). Much of the change related to HCP engagement was driven by the adoption of various technologies (estimated to be ~$6 billion per annum) including CRM, closed-loop marketing, campaign management, and multichannel marketing. According to Gartner, “By 2018, digital drug launches will be standard, with 80% of the top pharma companies announcing new products via at least five digital channels”.
On the occasion, Manish Gupta, CEO, Indegene, stated, “We see a step change in how HCPs want to engage with life sciences manufacturers, and are committed to accelerating innovation through our significant investments to address this challenging shift. We have now acquired two specialized software product offerings in this space and launched the Omnipresence for Lifesciences™ suite of technologies to address critical gaps in HCP experience and coverage from an omnichannel standpoint. We now have customers using our software products in over 50 countries across a broad range of regulatory and health system environments.”
“We’re delighted to partner with Skura as they share our transformational vision for the industry and are respected thought leaders in life sciences sales enablement. With this acquisition we’re also now looking to make Toronto our next product innovation hub in addition to Montreal, Los Angeles, and Bangalore,” said Rajesh Nair, President, Indegene.
“We see tremendous opportunity for our existing life sciences customers to leverage Indegene’s portfolio of omnichannel solutions to bring them closer to their desired business outcomes, as well as for our platforms to reach a broader audience through Indegene’s global presence and deep partnership with the industry. We’re delighted to partner with Indegene.” said Chris Skura, CEO, Skura Corporation.
